Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Alnylam Pharmaceuticals Inc R&D Day 2020 (Event 2) Transcript

Dec 16, 2020 / 02:00PM GMT
Release Date Price: $138.32 (+1.93%)
Christine Regan Lindenboom
Alnylam Pharmaceuticals, Inc. - Senior VP of IR & Corporate Communications

Good morning, and welcome to day 2 of our Virtual Alnylam R&D Day event. I'm Christine Lindenboom, Senior Vice President of investor relations and Corporate Communications at Alnylam. With me today are Dr. Arun Sanyal, Virginia Commonwealth University School of Medicine; and Josh Friedman, Senior Director of Clinical Research at Alnylam, who will discuss succeeding in NASH with genetically validated targets. Pushkal Garg, Chief Medical Officer at Alnylam, will cover progress from our earlier-stage clinical pipeline. Kevin Fitzgerald, Chief Scientific Officer at Alnylam, will discuss opportunities beyond the liver with RNAi therapeutics and we will close with an update on our path to a self-sustainable financial profile with Alnylam's CFO, Jeff Poulton.

Before I hand it over to Josh Freeman, I'd like to start with a few brief comments. Today's event is expected to run until approximately noon eastern standard time. Akshay will moderate a Q&A session at the conclusion of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot